Dongdong Yao
Sanford-Burnham Institute for Medical Research
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dongdong Yao.
Nature | 2006
Takashi Uehara; Tomohiro Nakamura; Dongdong Yao; Zhong Qing Shi; Zezong Gu; Yuliang Ma; Eliezer Masliah; Yasuyuki Nomura; Stuart A. Lipton
Stress proteins located in the cytosol or endoplasmic reticulum (ER) maintain cell homeostasis and afford tolerance to severe insults. In neurodegenerative diseases, several chaperones ameliorate the accumulation of misfolded proteins triggered by oxidative or nitrosative stress, or of mutated gene products. Although severe ER stress can induce apoptosis, the ER withstands relatively mild insults through the expression of stress proteins or chaperones such as glucose-regulated protein (GRP) and protein-disulphide isomerase (PDI), which assist in the maturation and transport of unfolded secretory proteins. PDI catalyses thiol–disulphide exchange, thus facilitating disulphide bond formation and rearrangement reactions. PDI has two domains that function as independent active sites with homology to the small, redox-active protein thioredoxin. During neurodegenerative disorders and cerebral ischaemia, the accumulation of immature and denatured proteins results in ER dysfunction, but the upregulation of PDI represents an adaptive response to protect neuronal cells. Here we show, in brains manifesting sporadic Parkinsons or Alzheimers disease, that PDI is S-nitrosylated, a reaction transferring a nitric oxide (NO) group to a critical cysteine thiol to affect protein function. NO-induced S-nitrosylation of PDI inhibits its enzymatic activity, leads to the accumulation of polyubiquitinated proteins, and activates the unfolded protein response. S-Nitrosylation also abrogates PDI-mediated attenuation of neuronal cell death triggered by ER stress, misfolded proteins or proteasome inhibition. Thus, PDI prevents neurotoxicity associated with ER stress and protein misfolding, but NO blocks this protective effect in neurodegenerative disorders through the S-nitrosylation of PDI.
Nature Medicine | 2009
Shu-ichi Okamoto; Mahmoud A. Pouladi; Maria Talantova; Dongdong Yao; Peng Xia; Dagmar E. Ehrnhoefer; Rameez Zaidi; Arjay Clemente; Marcus Kaul; Rona K. Graham; Dongxian Zhang; H-S Vincent Chen; Gary Tong; Michael R. Hayden; Stuart A. Lipton
Huntingtons disease is caused by an expanded CAG repeat in the gene encoding huntingtin (HTT), resulting in loss of striatal and cortical neurons. Given that the gene product is widely expressed, it remains unclear why neurons are selectively targeted. Here we show the relationship between synaptic and extrasynaptic activity, inclusion formation of mutant huntingtin protein (mtHtt) and neuronal survival. Synaptic N-methyl-D-aspartate–type glutamate receptor (NMDAR) activity induces mtHtt inclusions via a T complex-1 (TCP-1) ring complex (TRiC)-dependent mechanism, rendering neurons more resistant to mtHtt-mediated cell death. In contrast, stimulation of extrasynaptic NMDARs increases the vulnerability of mtHtt-containing neurons to cell death by impairing the neuroprotective cyclic AMP response element–binding protein (CREB)–peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) cascade and increasing the level of the small guanine nucleotide–binding protein Rhes, which is known to sumoylate and disaggregate mtHtt. Treatment of transgenic mice expressing a yeast artificial chromosome containing 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs and ameliorates neuropathological and behavioral manifestations. By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Our findings offer a rational therapeutic approach for protecting susceptible neurons in Huntingtons disease.
Journal of Biological Chemistry | 2000
Hélène Varoqui; Heming Zhu; Dongdong Yao; Hong Ming; Jeffrey D. Erickson
Glutamine is the preferred precursor for the neurotransmitter pool of glutamate, the major excitatory transmitter in the mammalian central nervous system. We have isolated a complementary DNA clone (designated GlnT) encoding a plasma membrane glutamine transporter from glutamatergic neurons in culture, and its properties have been examined using the T7 vaccinia system in fibroblasts. When GlnT is transfected into CV-1 cells, l-glutamine is the preferred substrate. Transport is Na+-dependent and inhibited by α-methylaminoisobutyric acid, a specific inhibitor of neutral amino acid transport system A. Kinetic analysis of glutamine uptake by GlnT is saturable, with a Michaelis constant (K m ) of 489 ± 88 μm at pH 7.4. Glutamine uptake mediated by GlnT is pH-sensitive with a 5-fold greater efficiency of uptake at pH 8.2 than at pH 6.6. Only the maximal velocity of transport increases without a significant change in K m . The distribution of GlnT mRNA and protein in the central nervous system is widespread and is expressed on neurons that use glutamate as their neurotransmitter. In cultured cerebellar granule cells, GlnT is expressed only on neurons and is absent from astrocytes. GlnT expression increases concomitantly with the morphologic and functional differentiation of these cells in vitro, consistent with its role of supplying glutamatergic neurons with their neurotransmitter precursor. GlnT is the first member of the system A family of neutral amino acid transporters with 11 putative membrane-spanning domains and is a potential target to modulate presynaptic glutamatergic function.
Journal of Biological Chemistry | 2000
Dongdong Yao; Bryan Mackenzie; Hong Ming; Hélène Varoqui; Heming Zhu; Matthias A. Hediger; Jeffrey D. Erickson
A cDNA clone encoding a plasma membrane alanine-preferring transporter (SAT2) has been isolated from glutamatergic neurons in culture and represents the second member of the system A family of neutral amino acid transporters. SAT2 displays a widespread distribution and is expressed in most tissues, including heart, adrenal gland, skeletal muscle, stomach, fat, brain, spinal cord, colon, and lung, with lower levels detected in spleen. No signal is detected in liver or testis. In the central nervous system, SAT2 is expressed in neurons. SAT2 is significantly up-regulated during differentiation of cerebellar granule cells and is absent from astrocytes in primary culture. The functional properties of SAT2, examined using transfected fibroblasts and in cRNA-injected voltage-clamped Xenopus oocytes, show that small aliphatic neutral amino acids are preferred substrates and that transport is voltage- and Na+-dependent (1:1 stoichiometry), pH-sensitive, and inhibited by α-(methylamino)isobutyric acid (MeAIB), a specific inhibitor of system A. Kinetic analyses of alanine and MeAIB uptake by SAT2 are saturable, with Michaelis constants (K m ) of 200–500 μm. In addition to its ubiquitous role as a substrate for oxidative metabolism and a major vehicle of nitrogen transport, SAT2 may provide alanine to function as the amino group donor to α-ketoglutarate to provide an alternative source for neurotransmitter synthesis in glutamatergic neurons.
Molecular Neurodegeneration | 2011
Fanjun Meng; Dongdong Yao; Yang Shi; Jonathan Kabakoff; Wei Wu; Joshua Reicher; Yuliang Ma; Bernd Moosmann; Eliezer Masliah; Stuart A. Lipton; Zezong Gu
BackgroundAccumulation of aberrant proteins to form Lewy bodies (LBs) is a hallmark of Parkinsons disease (PD). Ubiquitination-mediated degradation of aberrant, misfolded proteins is critical for maintaining normal cell function. Emerging evidence suggests that oxidative/nitrosative stress compromises the precisely-regulated network of ubiquitination in PD, particularly affecting parkin E3 ligase activity, and contributes to the accumulation of toxic proteins and neuronal cell death.ResultsTo gain insight into the mechanism whereby cell stress alters parkin-mediated ubiquitination and LB formation, we investigated the effect of oxidative stress. We found significant increases in oxidation (sulfonation) and subsequent aggregation of parkin in SH-SY5Y cells exposed to the mitochondrial complex I inhibitor 1-methyl-4-phenlypyridinium (MPP+), representing an in vitro cell-based PD model. Exposure of these cells to direct oxidation via pathological doses of H2O2 induced a vicious cycle of increased followed by decreased parkin E3 ligase activity, similar to that previously reported following S-nitrosylation of parkin. Pre-incubation with catalase attenuated H2O2 accumulation, parkin sulfonation, and parkin aggregation. Mass spectrometry (MS) analysis revealed that H2O2 reacted with specific cysteine residues of parkin, resulting in sulfination/sulfonation in regions of the protein similar to those affected by parkin mutations in hereditary forms of PD. Immunohistochemistry or gel electrophoresis revealed an increase in aggregated parkin in rats and primates exposed to mitochondrial complex I inhibitors, as well as in postmortem human brain from patients with PD with LBs.ConclusionThese findings show that oxidative stress alters parkin E3 ligase activity, leading to dysfunction of the ubiquitin-proteasome system and potentially contributing to LB formation.
Cell Death & Differentiation | 2005
Zezong Gu; Tomohiro Nakamura; Dongdong Yao; Zhong Qing Shi; Stuart A. Lipton
How can common ‘sporadic’ forms of neurodegenerative disorders, such as Parkinson’s disease (PD) and Alzheimer’s disease, mimic very rare genetic mutations to cause a similar phenotype? We show here that abnormal protein accumulation and impaired protein degradation can result from environmental factors causing oxidative and nitrosative stress. On the occasion of this special issue dedicated to the ‘discovery of ubiquitin-mediated protein degradation,’ we review aberrant protein accumulation via dysfunction of ubiquitination because of nitrosative stress and the resulting clinical significance of this recent discovery to human neurodegenerative disorders, using PD as a model disease.
Proceedings of the National Academy of Sciences of the United States of America | 2004
Dongdong Yao; Zezong Gu; Tomohiro Nakamura; Zhong Qing Shi; Yuliang Ma; Benjamin Gaston; Lisa A. Palmer; Edward Rockenstein; Zhuohua Zhang; Eliezer Masliah; Takashi Uehara; Stuart A. Lipton
Science | 2005
Stuart A. Lipton; Tomohiro Nakamura; Dongdong Yao; Zhong Qing Shi; Takashi Uehara; Zezong Gu
Journal of Pharmacology and Experimental Therapeutics | 2001
Dennis Paul; Dongdong Yao; Peimin Zhu; Lerna D. Minor; Meredith Mason Garcia
Anesthesia & Analgesia | 2018
Hange Li; Mingzhang Zuo; Adrian W. Gelb; Biao Zhang; Xiaohui Zhao; Dongdong Yao; Di Xia; Yuguang Huang